 WUXI, China, April 6, 2021 PRNewswire -- WuXi Biologics WuXi Bio 2269.HK, a global company with leading open-access biologics technology platforms, today announced that it has successfully completed both a Pre-License Inspection PLI and a routine GMP inspection by the U.S. FDA FDA. The inspections focused on the two different innovative biologics manufactured at the companys facilities including MFG1, MFG2 and DP1 in Wuxi, China. 